芪苈强心胶囊联合曲美他嗪对冠心病慢性心力衰竭患者心功能及血浆脑钠肽水平变化的影响  

Effects of Qili Qiangxin Capsules Combined with Trimetazidine on Heart Function and Plasma Brain Natriuretic Peptide Levels in Patients with Coronary Heart Disease and Chronic Heart Failure

作　　者：金玉[1] JIN Yu(Department of Hypertension,Zhengzhou People’s Hospital,Zhengzhou,Henan,450000,China)

机构地区：[1]郑州人民医院高血压科,河南郑州450000

出　　处：《黑龙江医学》2022年第15期1866-1868,共3页Heilongjiang Medical Journal

摘　　要：目的:分析芪苈强心胶囊联合曲美他嗪在冠心病慢性心力衰竭(CHF)患者中的应用效果。方法:选取2019年1月—2020年1月郑州人民医院收治的158例冠心病CHF患者作为研究对象,所有患者均接受常规对症治疗,在此基础上予以曲美他嗪治疗的78例为对照组,接受芪苈强心胶囊、曲美他嗪联合治疗的80例患者为观察组,比较两组患者疗效、治疗前后心功能[左心室射血分数(LVEF)与左心室舒张末期内径(LVEDD)]、心肌损伤指标[心肌肌钙蛋白I (cTnI)、脑钠肽(BNP)]、炎性因子[血清超敏C反应蛋白(hs-CRP)与白介素-6 (IL-6)]及不良反应。结果:观察组总有效率高于对照组,差异有统计学意义(χ^(2)=7.439,P<0.05);治疗后,观察组LVEF水平高于对照组,LVEDD水平低于对照组,差异有统计学意义(t=4.787、3.857,P<0.05);治疗后,观察组BNP、cTnI水平低于对照组,差异有统计学意义(t=7.247、11.282,P<0.05);治疗后,观察组血清hs-CRP与IL-6水平均较对照组低,差异有统计学意义(t=8.469、10.591,P<0.05);观察组不良反应发生率7.50%与对照组3.85%相比,差异无统计学意义(χ^(2)=0.419,P>0.05)。结论:芪苈强心胶囊与曲美他嗪联合应用于冠心病CHF患者,可提高治疗效果,明显改善心功能,降低血浆BNP水平,还可减轻患者炎症反应,且不会明显增加药物不良反应。Objective: To analyze the effect of Qili Qiangxin capsule combined with trimetazidine in patients with coronary heart disease and chronic heart failure(CHF). Methods: A total of 158 CHF patients with CHF in the hospital from January 2019to January 2020 were retrospectively selected. All received routine symptomatic treatment, and 78 patients who received trimetazidine treatment on this basis were the control group. The 80 patients who received the combination therapy of Qili Qiangxin Capsule and trimetazidine were selected as the observation group. The efficacy, cardiac function, left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD), myocardial injury indexes cardiac troponin I(cTnI), brain natriuretic peptide(BNP), serum inflammatory factors high-sensitivity C-reactive protein(hs-CRP) and interleukin-6(IL-6) and adverse reactions were compared between the two groups before and after treatment. Results: The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant(χ^(2)=7.439, P<0.05). After treatment, the level of LVEF in the observation group was higher than that in the control group, and the level of LVEDD in the observation group was lower than that in the control group, and the differences were statistically significant(t=4.787, 3.857, P<0.05). After treatment, the levels of BNP and cTnI in the observation group were lower than those in the control group, and the difference was statistically significant(t=7.247, 11.282, P<0.05). After treatment, the levels of serum hs-CRP and IL-6 in the observation group were lower than those in the control group, and the difference was statistically significant(t=8.469, 10.591, P<0.05). The incidence of adverse reactions in the observation group was 7.50%, compared with 3.85% in the control group, the difference was not statistically significant(χ^(2)=0.419, P>0.05). Conclusion: The combination of Qiliqiangxin Capsule and trimetazidine in CHF patients with co

关 键 词：芪苈强心胶囊 冠心病 慢性心力衰竭 心功能 炎性因子 

分 类 号：R541.4[医药卫生—心血管疾病]